Sanofi stock forecast: Third-party price targets

Sanofi’s share price reflects the way a large, global pharmaceutical business interacts with markets on a day-to-day basis, responding to company updates, regulatory milestones and wider equity trends.

By Dan Mitchell4 hours ago

Doctor with a stethoscope and medical icons in the background. — Photo: Shutterstock

Sanofi (SAN) is trading around €83.41 as of 11:54am on 9 January 2026 (UTC), within an intraday range of €82.55–€83.60 on Capital.com’s euro-denominated stock CFD for the French listing. Past performance is not a reliable indicator of future results.

The stock is trading amid a series of company-specific developments. These include Sanofi’s announcement that the US Food and Drug Administration has accepted a priority review application to extend the use of its type 1 diabetes drug Tzield to younger children, with a decision expected in late April 2026 (Sanofi, 5 January 2026). Recent trading has also taken place against the backdrop of additional strategic updates, including an AI-enabled autoimmune drug discovery collaboration with Earendil Labs valued at up to $2.56 billion (BioXconomy, 7 January 2026), alongside support for a $30 million investment in Enable Injections to expand manufacturing capacity for its enFuse drug-delivery platform (GlobeNewsWire, 6 January 2026).

Sanofi stock forecast 2026–2030: Third-party price targets

As of 9 January 2026, third-party Sanofi stock predictions reflect a range of external views on the pharmaceutical group’s earnings outlook, regulatory pipeline and sector positioning into 2026. These are external opinions only and do not guarantee future performance.

Jefferies (single-stock research)

Jefferies maintains a 12-month SAN stock forecast of €100.00 for the group’s US- and Paris-listed shares, reiterating a buy recommendation despite a US regulatory setback for multiple sclerosis drug ‘tolebrutinib’. The broker cites continued confidence in Sanofi’s wider drug pipeline and notes that returns from the company’s 2020 cohort of launches are improving, while also flagging communication and execution risks around specific programmes (Investing.com, 24 December 2025).

Directorstalk / consensus snapshot (aggregated analyst view)

A 14 December 2025 summary of Wall Street coverage reports an average 12-month SAN stock forecast of about $60.13 per American depositary share, implying upside of roughly 23.5% from the then-prevailing price, based on 10 contributing analyst estimates. The write-up notes that eight analysts rate the stock a buy and two a hold, reflecting expectations for earnings growth and pipeline delivery, while also acknowledging execution and regulatory risks (DirectorsTalk Interviews, 15 December 2025).

TipRanks (multi-analyst aggregation)

TipRanks shows an average 12-month Sanofi price target of about €122.53, with individual forecasts ranging from approximately €85.35 to €119.48. The service reports that this range is based on 13 Wall Street analysts’ targets published over the prior three months, incorporating assumptions around revenue trends, margins and ongoing research and development investment (TipRanks, 9 January 2026).

Fintel (broker consensus summary)

An update published in December 2025 cites an average one-year Sanofi price target of $124.21 per SNYNF share, with estimates ranging from $109.79 to $149.94. This implied approximately 29.3% upside from the referenced closing price. The note reports Intesa Sanpaolo Equity Research maintaining a buy recommendation and attributes these targets to expectations for earnings growth and value from the late-stage pipeline, while also noting typical regulatory and competitive uncertainties associated with the pharmaceutical sector (Nasdaq, 16 December 2025).

Third-party Sanofi stock predictions clustered in the high double-digit euro range or roughly $60–$125 per share around December 2025–January 2026. Rationales generally link potential upside or downside to pipeline execution, regulatory outcomes and revenue delivery, rather than short-term share price fluctuations.

Predictions and third-party forecasts are inherently uncertain, as they cannot fully account for unexpected market developments. Past performance is not a reliable indicator of future results.

SAN price: Technical overview

Sanofi (SAN) holds around €83.41 as of 11:54am on 9 January 2026 (UTC), with price trading just above the 10-, 20- and 30-day simple moving-average cluster near €82–€83, and below the 50-, 100- and 200-day moving averages around €84–€86. This positioning leaves the broader daily trend mixed. The 14-day RSI, at approximately 52, sits in neutral territory, while an ADX reading near 26 suggests an established but moderate trend environment rather than a strongly directional move.

On the topside, the nearest classic pivot above the market is R1 around €87.31, with a daily close above that level bringing the €91.92 R2 area into focus as the next potential resistance zone. The classic pivot near €82.66 acts as initial support on pullbacks, while the 100-day simple moving average close to €84 forms a nearby moving-average reference. A sustained break below this region could increase the risk of a move towards S1 around €78.06 if downside momentum builds (TradingView, 9 January 2026).

This technical analysis is for informational purposes only and does not constitute financial advice or a recommendation to buy or sell any instrument.

Sanofi share price history (2024–2026)

SAN’s stock price has seen a clear shift over the past two years, moving from the mid-€90s in early January 2024 to the low-€80s by early January 2026. The stock closed around €94–€96 through much of January 2024 and traded largely within a €90–€100 range for the remainder of the year, before pushing above €110 on an intraday basis in March 2025 and briefly returning towards €100 in April.

During the second half of 2025, the price gradually eased from the high-€80s and low-€90s into the high-€70s to low-€80s range. Sanofi ended 2025 at €83.00 and settled at €82.91 on 8 January 2026, placing it roughly 10–15% below levels observed in early 2025.

Past performance is not a reliable indicator of future results.

Sanofi (SAN): Capital.com analyst view

The SAN stock price has eased back over the past year, moving from levels around €95–€100 in early 2024 to the low-€80s by early January 2026, including a close at €82.91 on 8 January 2026. This pullback follows a period of higher volatility, during which the stock briefly traded above €110 in March 2025 before gradually slipping back into the high-€70s to low-€80s area towards year-end. The move illustrates how shifts in earnings expectations, regulatory developments and broader equity market conditions can feed through to short-term price behaviour.

From a fundamental perspective, Sanofi’s recent communications have highlighted solid sales growth, increasing contributions from newer product launches and a stated focus on operating as a more streamlined biopharma group. Some market participants view these factors as potentially supportive over the medium term. An alternative view is that higher research and development spending, execution risks around late-stage assets and sensitivity to healthcare policy changes could continue to weigh on the share price, particularly if results or guidance fall short of expectations or broader risk appetite weakens.

CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. Past performance is not a reliable indicator of future results.

Summary – Sanofi stock price 2026

Sanofi’s share price started 2025 around €94–€96 and ended the year at €83.00, representing a decline over the calendar year.
The stock traded above €110 in March 2025 before gradually moving back into the high-€70s to low-€80s range by late December, underscoring notable intra-year volatility.
Intraday ranges during 2025 frequently spanned €1–€3, pointing to active trading conditions without a sustained directional trend for much of the year.
Key company updates on earnings, guidance and pipeline progress featured alongside broader equity market movements as recurring reference points for Sanofi’s price action.

Past performance is not a reliable indicator of future results.

FAQ

Who owns the most Sanofi stock?

Sanofi has a widely distributed shareholder base, which is typical of large, publicly listed pharmaceutical companies. Its largest shareholders are institutional investors, including global asset managers and pension funds, which together hold a substantial proportion of the company’s outstanding shares. The French state also retains a strategic interest through public investment vehicles. No single shareholder holds a controlling stake, meaning Sanofi operates with a broadly diversified ownership structure.

What is the 5-year Sanofi share price forecast?

There is no single agreed five-year share price forecast for Sanofi, as long-term projections vary widely between analysts and are subject to uncertainty. Longer-dated outlooks tend to focus on factors such as pipeline development, regulatory outcomes, patent cycles and healthcare policy trends, rather than setting specific price targets. Any multi-year forecast should be viewed as a scenario rather than a prediction, as both market conditions and company performance can change over time.

Is Sanofi a good stock to buy?

Whether Sanofi is considered attractive depends on an individual’s objectives, time horizon and risk tolerance. Some market participants focus on the company’s scale, product portfolio and research pipeline, while others point to regulatory risk, research and development costs, and competitive pressures within the pharmaceutical sector. Share prices reflect how these factors are assessed and re-assessed over time. This information is provided for context only and does not constitute a recommendation or investment advice.

Could Sanofi stock go up or down?

Like all listed equities, Sanofi’s share price can move both up and down. Price movements may reflect company-specific developments such as earnings results, drug approvals or pipeline setbacks, as well as broader market conditions, currency movements and changes in investor sentiment. Pharmaceutical stocks can also react to regulatory decisions and healthcare policy changes. Past price behaviour does not indicate future performance, and volatility can occur over both short and longer timeframes.

Should I invest in Sanofi stock?

Deciding whether to invest in Sanofi is a personal decision that depends on financial circumstances, risk appetite and investment goals. Investing in shares involves exposure to market risk, and prices can fall as well as rise. Carrying out independent research is an important part of the decision-making process, and some individuals may choose to seek guidance from a qualified professional. This article provides market information only and does not offer guidance on whether any investment is suitable.

How can traders gain exposure to Sanofi using CFDs on Capital.com?

Trading Sanofi CFDs on Capital.com lets you speculate on price movements without owning the underlying asset and to take long or short positions. However, contracts for difference (CFDs) are traded on margin, and leverage amplifies both profits and losses. You should ensure you understand how CFD trading works, assess your risk tolerance, and recognise that losses can occur quickly.